CBD for Cannabidiol

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Cannabidiol+1 MoreIntradermal Capsaicin - Drug
Eligibility
18 - 55
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether CBD can help reduce inflammation in the brain and help lessen pain sensitization.

Eligible Conditions
  • Cannabidiol
  • Healthy Subjects

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 10 Days

10 Days
Capsaicin-induced hyperalgesia
Microglial activation using [11C]PBR28 PET imaging

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

CBD
1 of 2
Placebo
1 of 2

Active Control

Non-Treatment Group

15 Total Participants · 2 Treatment Groups

Primary Treatment: CBD · Has Placebo Group · Phase < 1

CBDActiveComparator Group · 3 Interventions: Intradermal Capsaicin, [11C]PBR28, Low-dose lipopolysaccharide · Intervention Types: Drug, Radiation, Drug
PlaceboPlaceboComparator Group · 3 Interventions: Intradermal Capsaicin, [11C]PBR28, Low-dose lipopolysaccharide · Intervention Types: Drug, Radiation, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 10 days

Who is running the clinical trial?

National Center for Complementary and Integrative Health (NCCIH)NIH
781 Previous Clinical Trials
657,072 Total Patients Enrolled
Yale UniversityLead Sponsor
1,680 Previous Clinical Trials
21,088,244 Total Patients Enrolled
Rajiv Radhakrishnan, MDPrincipal Investigator - Yale University
Yale University
1 Previous Clinical Trials
18 Total Patients Enrolled

Eligibility Criteria

Age 18 - 55 · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
Connecticut66.7%
California33.3%
How old are they?
18 - 65100.0%
What site did they apply to?
Connecticut Mental Health Center100.0%
What portion of applicants met pre-screening criteria?
Met criteria66.7%
Did not meet criteria33.3%